These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1124 related articles for article (PubMed ID: 25993209)

  • 1. ABC, GCB, and Double-Hit Diffuse Large B-Cell Lymphoma: Does Subtype Make a Difference in Therapy Selection?
    Nowakowski GS; Czuczman MS
    Am Soc Clin Oncol Educ Book; 2015; ():e449-57. PubMed ID: 25993209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Should We Use Cell of Origin and Dual-protein Expression in Treating DLBCL?
    Riedell PA; Smith SM
    Clin Lymphoma Myeloma Leuk; 2018 Feb; 18(2):91-97. PubMed ID: 29352717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group.
    Staiger AM; Ziepert M; Horn H; Scott DW; Barth TFE; Bernd HW; Feller AC; Klapper W; Szczepanowski M; Hummel M; Stein H; Lenze D; Hansmann ML; Hartmann S; Möller P; Cogliatti S; Lenz G; Trümper L; Löffler M; Schmitz N; Pfreundschuh M; Rosenwald A; Ott G;
    J Clin Oncol; 2017 Aug; 35(22):2515-2526. PubMed ID: 28525305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review.
    Camicia R; Winkler HC; Hassa PO
    Mol Cancer; 2015 Dec; 14():207. PubMed ID: 26654227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stratifying diffuse large B-cell lymphoma patients treated with chemoimmunotherapy: GCB/non-GCB by immunohistochemistry is still a robust and feasible marker.
    Batlle-López A; González de Villambrosía S; Francisco M; Malatxeberria S; Sáez A; Montalban C; Sánchez L; Garcia J; González-Barca E; López-Hernández A; Ruiz-Marcellan MC; Mollejo M; Grande C; Richards KL; Hsi ED; Tzankov A; Visco C; Xu-Monette ZY; Cao X; Young KH; Piris MÁ; Conde E; Montes-Moreno S
    Oncotarget; 2016 Apr; 7(14):18036-49. PubMed ID: 26910115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of MYC rearrangements and "double hit" abnormalities in diffuse large B-cell lymphoma.
    Lin P; Medeiros LJ
    Curr Hematol Malig Rep; 2013 Sep; 8(3):243-52. PubMed ID: 23892979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Diffuse large B-cell lymphoma: therapeutic development based on clinical and biological heterogeneity].
    Miyazaki K
    Rinsho Ketsueki; 2015 Oct; 56(10):2047-55. PubMed ID: 26458444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diffuse large B-cell lymphoma.
    Li S; Young KH; Medeiros LJ
    Pathology; 2018 Jan; 50(1):74-87. PubMed ID: 29167021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is now the time for molecular driven therapy for diffuse large B-cell lymphoma?
    Di Rocco A; De Angelis F; Ansuinelli M; Foà R; Martelli M
    Expert Rev Hematol; 2017 Sep; 10(9):761-774. PubMed ID: 28712322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beyond RCHOP: A Blueprint for Diffuse Large B Cell Lymphoma Research.
    Nowakowski GS; Blum KA; Kahl BS; Friedberg JW; Baizer L; Little RF; Maloney DG; Sehn LH; Williams ME; Wilson WH; Leonard JP; Smith SM
    J Natl Cancer Inst; 2016 Dec; 108(12):. PubMed ID: 27986884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma.
    Dunleavy K; Pittaluga S; Czuczman MS; Dave SS; Wright G; Grant N; Shovlin M; Jaffe ES; Janik JE; Staudt LM; Wilson WH
    Blood; 2009 Jun; 113(24):6069-76. PubMed ID: 19380866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular background delineates outcome of double protein expressor diffuse large B-cell lymphoma.
    Meriranta L; Pasanen A; Alkodsi A; Haukka J; Karjalainen-Lindsberg ML; Leppä S
    Blood Adv; 2020 Aug; 4(15):3742-3753. PubMed ID: 32780847
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma.
    Fu K; Weisenburger DD; Choi WW; Perry KD; Smith LM; Shi X; Hans CP; Greiner TC; Bierman PJ; Bociek RG; Armitage JO; Chan WC; Vose JM
    J Clin Oncol; 2008 Oct; 26(28):4587-94. PubMed ID: 18662967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-Hodgkin's lymphoma: the old and the new.
    Cabanillas F
    Clin Lymphoma Myeloma Leuk; 2011 Jun; 11 Suppl 1():S87-90. PubMed ID: 22035756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study.
    Thieblemont C; Briere J; Mounier N; Voelker HU; Cuccuini W; Hirchaud E; Rosenwald A; Jack A; Sundstrom C; Cogliatti S; Trougouboff P; Boudova L; Ysebaert L; Soulier J; Chevalier C; Bron D; Schmitz N; Gaulard P; Houlgatte R; Gisselbrecht C
    J Clin Oncol; 2011 Nov; 29(31):4079-87. PubMed ID: 21947824
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetics and diffuse large B-Cell lymphoma.
    Niroula R; Butera J
    R I Med J (2013); 2015 Nov; 98(11):23-6. PubMed ID: 26517251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The significance of concurrent MYC and BCL2 expression in Egyptian patients with diffuse large B-cell NHL.
    Abdelhamid TM; Gaber AA; Abdelfattah RM; Algamal DA; Hamdy O; Mohamed G
    Pathol Res Pract; 2024 Jan; 253():154973. PubMed ID: 38101156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FOXP2-positive diffuse large B-cell lymphomas exhibit a poor response to R-CHOP therapy and distinct biological signatures.
    Wong KK; Gascoyne DM; Soilleux EJ; Lyne L; Spearman H; Roncador G; Pedersen LM; Møller MB; Green TM; Banham AH
    Oncotarget; 2016 Aug; 7(33):52940-52956. PubMed ID: 27224915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study.
    Nowakowski GS; LaPlant B; Macon WR; Reeder CB; Foran JM; Nelson GD; Thompson CA; Rivera CE; Inwards DJ; Micallef IN; Johnston PB; Porrata LF; Ansell SM; Gascoyne RD; Habermann TM; Witzig TE
    J Clin Oncol; 2015 Jan; 33(3):251-7. PubMed ID: 25135992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tissue microarray in a subset of South African patients with DLBCL.
    Sissolak G; Wood L; Smith L; Chan JW; Armitage J; Jacobs P
    Transfus Apher Sci; 2013 Oct; 49(2):120-32. PubMed ID: 23942329
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 57.